Hikma Pharmaceuticals Public annual working capital
2020
2021
2022
2023
2024
2025
Hikma Pharmaceuticals Public Working Capital Growth & History (HIK)
Hikma Pharmaceuticals Public's working capital was $1.19B for fiscal 2025.
View full Hikma Pharmaceuticals Public company overviewHikma Pharmaceuticals Public annual working capital history
| Fiscal year | Period ended | Working capital | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $1.19B | $905.0M | +317.54% |
| 2024 | 2024-12-31 | $285.0M | −$476.0M | −62.55% |
| 2023 | 2023-12-31 | $761.0M | −$161.0M | −17.46% |
| 2022 | 2022-12-31 | $922.0M | −$156.0M | −14.47% |
| 2021 | 2021-12-31 | $1.08B | $184.0M | +20.58% |
| 2020 | 2020-12-31 | $894.0M | — | — |
Hikma Pharmaceuticals Public quarterly working capital
Q4.24
Q4.25
Q2.26
| Fiscal quarter | Period ended | Working capital | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $1.36B | — | — |
| Q4 2025 | 2025-12-31 | $1.19B | $905.0M | +317.54% |
| Q4 2024 | 2024-12-31 | $285.0M | — | — |
Hikma Pharmaceuticals Public working capital trends
Over the last five fiscal years, Hikma Pharmaceuticals Public's working capital increased from $894.0M to $1.19B, a change of $296.0M. The latest reported quarter, Q2 2026, shows $1.36B.
About the metric
What working capital means
Working capital is the difference between current assets and current liabilities. It provides a snapshot of short-term operating liquidity, although negative working capital can be normal for some business models and the measure is often not meaningful for banks.
Calculation and source
How working capital is calculated
TickerStat calculates working capital as reported current assets minus reported current liabilities at the same balance-sheet date. Missing current classifications are not assumed to be zero. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Hikma Pharmaceuticals Public source filings ↗Community posts
Hikma’s epinephrine nasal spray advances into regulatory review
Hikma ($HIK) said regulators in the United States, Europe and the UK have accepted submissions for its investigational epinephrine nasal spray for review. The company has also filed in Canada and intends to expand submissions to additional ...